NCT07309601 Sucrase-Isomaltase (SI) Genes and Meal Load
| NCT ID | NCT07309601 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | IBS - Irritable Bowel Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2026-02-01 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional study is to examine whether those patients with irritable bowel syndrome (IBS) and a reduced abitility do degrade starch and sugar (lowe levels of enzymes) have lower raise in blood glucose after a meal than those with normal expression of enzymes. We also want to examine whether those IBS patients with reduced enzyme levels have increased bowel symptom in relation to this meal. The main questions it aims to answer are: Does reduced ability to degrade starch and sugar due to less enzyme activity lead to lower increase in blood glucose after a meal? Does reduced ability to degrade starch and sugar due to less enzyme activity lead to increased bowel symptoms after a meal?
Eligibility Criteria
Inclusion Criteria: * Diagnosis of irritable bowel syndrome (IBS) * Gene testing has been conducted regarding genes regulating the production of sucrase-isomaltase ensymes in previous dietary interventions using the starch- and sucrose reduced diet (SSRD) or multi-center study. Exclusion Criteria: * Diagnosis of inflammatory bowel disease, celiac disease, bile salt malabsorption, gastroenteritis or enteric dysmotility * Severe food allergy * Serious heart-, lung-, cardiovascular-, malignant- or mental illness * Ongoing eating disorder * Pregnancy * Recent major gastrointestinal surgery * Alcohol and/or drug addiction
Contact & Investigator
Cecilia Kennbäck, Registered Nurse
STUDY CHAIR
Department of Internal Medicine, Skåne University Hospital, 20502 Malmö
Frequently Asked Questions
Who can join the NCT07309601 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying IBS - Irritable Bowel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07309601 currently recruiting?
Yes, NCT07309601 is actively recruiting participants. Contact the research team at bodil.ohlsson@med.lu.se for enrollment information.
Where is the NCT07309601 trial being conducted?
This trial is being conducted at Malmö, Sweden.
Who is sponsoring the NCT07309601 clinical trial?
NCT07309601 is sponsored by Region Skane. The principal investigator is Cecilia Kennbäck, Registered Nurse at Department of Internal Medicine, Skåne University Hospital, 20502 Malmö. The trial plans to enroll 70 participants.